Gov. Mike Braun dropped into Ossium Health’s Indianapolis bone marrow production facility on Tuesday, putting a public spotlight on what the company bills as a first-of-its-kind bone marrow bank. The startup harvests and cryopreserves marrow from deceased organ donors to create an on-demand supply for transplants and research.
Braun Tours Indianapolis Facility
Ossium co-founders Kevin Caldwell and Erik Woods walked the governor through the operation, detailing the bank’s recovery, processing and freezer systems, according to WISH-TV. The outlet reports that Braun visited the site on April 7 and met with scientists working on vertebral-bone recovery and HLA typing. The tour offered a rare public look at a company that has quietly expanded its Indianapolis footprint over the past several years.
How Ossium’s Marrow Bank Works
Ossium says it recovers bone marrow and bone material from the vertebral columns of consented, rigorously screened deceased organ donors, then processes that tissue under controlled laboratory conditions and cryopreserves units for long-term storage, according to Ossium Health. Those frozen units can be HLA-typed and made available to transplant centers, a system the company pitches as a way to shorten wait times for matched graft material and to support follow-up infusions when needed. Company materials also point to orthopedic uses for the recovered bone material.
Clinical Trials And Federal Support
Ossium is the sponsor of PRESERVE I (NCT05589896), a phase 1/2 clinical trial that tests cryopreserved, deceased-donor bone marrow transplants in patients with hematologic malignancies, according to ClinicalTrials.gov. The company has also landed a contract with the Biomedical Advanced Research and Development Authority, or BARDA, to advance ready-to-use marrow for radiological and nuclear emergency response, as detailed in a press release from BusinessWire. Together, the clinical program and federal backing support Ossium’s argument that off-the-shelf marrow could expand access and speed care in both routine treatment and rare crises.
Why State Leaders Are Betting On It
The visit came as state officials are rolling out a major life sciences push. The Indiana Economic Development Corporation has outlined a $1 billion, performance-based commitment aimed at growing agriculture and life sciences jobs over the next decade. In press coverage of the tour, Caldwell pointed to Indianapolis logistics as a quiet advantage, saying the company can deliver biosciences products anywhere in the continental United States within one or two days, he told WISH-TV. Braun’s office has said the new incentives will be tied to measurable outcomes and regional stewardship in an effort to keep the spending accountable.
Local Context And What’s Next
Local business reporting has followed Ossium’s steady scaling and hiring at its West 74th Street production site, highlighting the company’s shift from research and development into clinical activity, according to the Indianapolis Business Journal. As Ossium continues enrolling patients in PRESERVE I, both state officials and company leaders point to upcoming clinical readouts, federal program work and additional hiring as the next big checkpoints tied to Indiana’s life sciences strategy. If the trials ultimately confirm safety and efficacy, the company argues that frozen, donor-derived marrow could reshape how hospitals manage transplants and how states prepare for rare public health emergencies.
